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Background: Although genetic variation is believed to contribute to an individual’s susceptibility to major
depressive disorder, genome-wide association studies have not yet identified associations that could explain the full
etiology of the disease. Epigenetics is increasingly believed to play a major role in the development of common
clinical phenotypes, including major depressive disorder.
Results: Genome-wide MeDIP-Sequencing was carried out on a total of 50 monozygotic twin pairs from the
UK and Australia that are discordant for depression. We show that major depressive disorder is associated with
significant hypermethylation within the coding region of ZBTB20, and is replicated in an independent cohort of 356
unrelated case-control individuals. The twins with major depressive disorder also show increased global variation in
methylation in comparison with their unaffected co-twins. ZBTB20 plays an essential role in the specification of the
Cornu Ammonis-1 field identity in the developing hippocampus, a region previously implicated in the development
of major depressive disorder.
Conclusions: Our results suggest that aberrant methylation profiles affecting the hippocampus are associated with
major depressive disorder and show the potential of the epigenetic twin model in neuro-psychiatric disease.Background
During development, dynamic changes to the epigenome
play a critical role in establishing and maintaining each
tissue within the body [1,2]. In particular, DNA methyla-
tion has been shown to play a critical role in the devel-
opment of sub-regions of the brain. Epigenetic processes
control several neurobiological and cognitive processes,
including neurogenesis, the limbic system, neuronal ac-
tivity, learning and memory, drug addiction, neurode-
generation and circadian rhythm [3]. Mutations in the
methyl CpG binding protein 2 gene (MECP2) have been
shown to lead to neurodevelopmental deficits, such as
those associated with Rett syndrome [4], and aberrant
DNA methylation signatures have been observed in* Correspondence: matthew.1.davies@kcl.ac.uk
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unless otherwise stated.several neuropsychiatric disorders, including schizophre-
nia and bipolar disorder [5]. There is considerable inter-
est, therefore, in investigating the role of epigenetics in
the development of other psychiatric diseases, such as
major depressive disorder (MDD) [3,6-10].
Although genetic variation and environmental stressors
are believed to increase an individual’s susceptibility to
MDD, genome-wide association studies have not yet identi-
fied any replicated associations with depression that could
explain the full etiology of the disease [3,11]. Twin studies
of MDD have estimated its heritability to be approximately
37% [12], but may be higher for recurrent and early onset
MDD [13]. However, the majority of monozygotic twin
(MZT) pairs are discordant for MDD (only 20% of male
and 38% of female MZT pairs show concordance for the
disorder under the DSM-IV criteria [14]).
Several lines of evidence suggest a role for epigenetic
factors in the development of depression. The delayed on-
set of the condition along with its episodic nature strongly
suggests that it may have an epigenetic component [3].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that epigenetic processes may play an essential role in
the pathology of the disease. In particular, several mice
studies showed that the antidepressants imipramine,
tranylcypromine and fluoxetine were able to induce
epigenetic changes [15]. A human study comparing 39
unrelated, postmortem frontal cortex MDD samples to
26 controls [16] identified several differentially methyl-
ated regions enriched for neuronal growth and develop-
mental genes, although these failed to replicate. Uddin
et al. [17] compared blood methylation profiles of 33
subjects with a lifetime history of depression and 67
non-depressed adults using the 27k array and demon-
strated that genome-wide methylation profiles distinguish
between depressed and non-depressed individuals. It has
been suggested that childhood adversities could increase
depression risk via epigenetic mechanisms [6,18-22].
There is also increasing evidence to suggest that epigen-
etic variation between MZT pairs may play a key role in
the etiology of psychopathology and contribute to pheno-
typic disconcordance [23].
In this study we used methylated DNA immunoprecipi-
tation combined with ultra-deep sequencing (MeDIP-seq)
to provide comprehensive coverage of the methylomic
landscape in order to compare blood samples between
MZT pairs discordant for MDD in two independent data-
sets (Figure 1). The first cohort (UK) comprised 27 dis-
cordant twin pairs from the UK while the second cohort
(Australia) comprised 23 discordant pairs from Australia.
Discordant MZT pairs constitute a powerful design for
epigenetic studies, as the genomic DNA sequence is iden-
tical within twin pairs and SNPs and other DNA sequence
variations are not confounding factors. Additionally, twin
pairs are generally exposed to similar environmental influ-
ences and important age and cohort effects are controlled
within the paired comparison.
Results and discussion
The regression analysis of the 27 UK discordant MZT pairs
alone did not clearly identify any differentially methylated
region (DMR) of genome-wide significance (using a conser-
vative significance level of 9 × 10-10; Table S1 in Additional
file 1). However, several of the most differentially methyl-
ated genes were related to the pathology of MDD, namely
CADPS1, PTPRM and ZBTB20 (zinc finger and BTB
domain containing 20 gene). Similarly, the regression ana-
lysis of 23 Australian discordant MZT pairs did not identify
any DMR of genome-wide significance (Table S4 in
Additional file 1). The second most differentially methyl-
ated gene (EPHB1), however, was related to the etiology of
MDD (Additional file 1). The meta-analysis of both UK
and Australian datasets identified 17 DMRs of genome-
wide significance (P < 0.05, Bonferoni adjusted for approxi-
mately 11 M tests; Table 1; Figure 2). Four of these 17DMRs were located within genes related to the pathology
of MDD, namely ZBTB20, AGTPBP1, TBC1D8 and
CLSTN1, and selected for replication. The region was repli-
cated in an independent replication cohort of 354 unre-
lated, age-matched females and showed an increased
methylation of 28.2% in the 118 MDD cases compared to
the 236 controls (P = 0.018, t-test; Figure 3a,b). A linear
regression model of the ZBTB20 region run on the inde-
pendent case-control samples adjusting for age, body mass
index (BMI) and smoking status retained significance
(P = 0.0487). ZBTB20 contains the second most signifi-
cantly differentially methylated region identified in the
meta-analysis, with an increased methylation level in cases
(P = 0.00048, Bonferoni adjusted for approximately 11 M
tests). The gene plays an essential role in the specification
of the Cornu Ammonis-1 (CA1) field identity in the de-
veloping hippocampus. The RPM (reads per millions)
value of the DMR is consistently higher in the depressed
cohort in relation to the control (Figure 3c).
Observed methylation changes do not relate to anti-
depressant use
The identified DMRs associated with MDD could reflect
the consequence rather than the cause of the disorder.
One possible consequence is use of anti-depressant
medication, which was assessed as a confounder for the
UK MZT pairs, for whom a record of drug usage was
available. Two additional linear mixed models were cal-
culated. The first included those individuals taking anti-
depressant medication as an additional factor, the second
eliminated twin pairs where the depressed twin was tak-
ing medication. Both produced results relatively consist-
ent with the UK linear mixed model, suggesting that the
observed methylation differences are not caused by anti-
depressant medication based on data available to us
(Tables S1, S2 and S3 in Additional file 1). ZBTB20 is
significantly associated with MDD to an unadjusted
P-value of 2.99 × 10-7 if anti-depressant medication is
included in the regression model and significant to a
P-value of 1.28 × 10-5 even if all depressed individuals tak-
ing medication are removed from the study. The β coeffi-
cient of the DMR also remains consistent with the full
linear model giving a β value of 1.073. Two other linear
models, one where the anti-depressant medication was in-
cluded as a co-factor and one where the model removed
medicated twin pairs completely, produced β coefficients
of 1.078 and 1.082, respectively. No association was ob-
served between cell count and calculated methylation
levels for the most significant DMRs in the UK linear
mixed model (see Materials and methods).
Our MeDIP-seq data indicated that twins with MDD
had a significantly increased variance in methylation when
compared with their unaffected co-twin. Comparison of
variance in global methylation between the depressed twin
Figure 1 Genomic methylation profiles of a female monozygotic twin pair discordant for major depressive disorder (MeDIP-seq data
of depressed and non-depressed twin shown in red and green, respectively). Although the overall patterns are extremely similar, differential
methylation does occur at specific loci.
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increased genome-wide variance in twins with MDD in
both the UK and Australian cohorts (P < 2.2 × 10-16 in
both datasets). This is in agreement with Byrne et al. [24],
who used the much sparser 450 k array but also reported
increased variance of methylation in the affected twin in a
cohort of 12 MZT pairs, a subsample of the current
Australian cohort. Byrne et al. failed to find any genome-
wide significant DMRs in the 12 MZT pairs discordant for
MDD. This could be the result of a limited sample sizeand/or the usage of the 450 k array, which has a much
lower resolution than MeDIP-seq [25].
Several mouse studies have already demonstrated the
importance of ZBTB20 for normal hippocampal function.
ZTBT20 targets hippocampal neurons as well as cerebel-
lum granule cells [26], consistent with our observation of
a high ZTBT20 expression in the hippocampal, cerebellum
and white matter regions of the brain. Conditionally delet-
ing ZBTB20 specifically in mature CA1 pyramidal neu-
rons impairs long-term potentiation and NMDA receptor
Table 1 Meta-analysis of 54 UK and 46 Australian blood samples using a fixed effects model approach
Chromosome Start Stop P-value Adjusted P-value Gene start Gene stop Gene name Distance Description
Chr5 63738001 63738501 1.75E-11 0.00019 63802451 63908121 RGS7BP 63950 Regulator of G-protein signaling 7 binding protein
Chr3 114618751 114619251 4.34E-11 0.00048 114056946 114866127 ZBTB20 - Zinc finger and BTB domain containing 20
Chr1 120633001 120633501 1.12E-10 0.00125 120454175 120612317 NOTCH2 20684 Notch homolog 2 (Drosophila)
Chr9 84715501 84716001 1.47E-10 0.00164 84603686 84610171 FLJ46321 105330 FAM75-like protein FLJ46321
Chr1 9845751 9846251 1.58E-10 0.00176 9789078 9884550 CLSTN1 - Calsyntenin 1
Chr9 88306501 88307001 2.02E-10 0.00225 88161453 88356944 AGTPBP1 - ATP/GTP binding protein 1
Chr3 36140001 36140501 4.93E-10 0.00549 36422096 36589496 STAC 281595 SH3 and cysteine rich domain
Chr7 17309251 17309751 1.35E-09 0.01503 17338275 17385775 AHR 28524 Aryl hydrocarbon receptor
Chr1 166550001 166550501 1.56E-09 0.01737 166573152 166594473 FMO9P 22651 Flavin containing monooxygenase 9 pseudogene
Chr3 66970001 66970501 1.69E-09 0.01881 67048726 67061632 KBTBD8 78225 Kelch repeat and BTB (POZ) domain
Chr12 132823251 132823751 2.30E-09 0.02560 132680916 132905905 GALNT9 - UDP-N-acetyl-alpha-D-galactosamine
Chr2 101764501 101765001 2.91E-09 0.03239 101623689 101767846 TBC1D8 - TBC1 domain family, member 8
Chr12 57688251 57688751 3.37E-09 0.03752 57647547 57704246 R3HDM2 - R3H domain containing 2
Chr2 221655001 221655501 3.42E-09 0.03807 222282746 222437010 EPHA4 627245 EPH receptor A4
Chr4 182369251 182369751 3.63E-09 0.04041 181985242 182080302 LINC00290 288949 Long intergenic non-protein coding RNA 290
Chr6 24236501 24237001 3.88E-09 0.04319 24171982 24358280 DCDC2 - Double cortin domain containing 2
Chr4 15620251 15620751 4.30E-09 0.04787 15606006 15657035 FBXL5 - F-box and leucine-rich repeat protein 5
Chr4 170932501 170933001 4.65E-09 0.05177 170907747 170947429 MFAP3L - Microfibrillar-associated protein 3-like
Chr16 55912001 55912501 4.93E-09 0.05488 55880065 55989943 CES5A - Carboxylesterase 5A
Chr12 126885001 126885501 5.67E-09 0.06312 126927026 126957331 LOC100128554 41525 Uncharacterized LOC100128554
Chr10 22007501 22008001 6.22E-09 0.06924 21823100 22032559 MLLT10 - Myeloid/lymphoid leukemia
Chr1 172293751 172294251 6.57E-09 0.07314 171810620 172381857 DNM3 - Dynamin 3
Chr1 75392751 75393251 6.61E-09 0.07358 75198861 75232360 TYW3 160391 tRNA-yW synthesizing protein 3
The nearest gene feature to a DMR is shown, DMRs occurring within a coding region are shown in bold. Bonferoni adjusted P-values with a significance <0.01 are also shown in bold.
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Figure 2 Manhattan plot showing the P-values of approximately 10 M 500 bp bins from the meta analysis with the ZBTB20 DMR
identified in the plot.
Figure 3 (A,B) Replication of differentially methylated genes in an independent case-control cohort of 118 depressed and 236 control
unrelated females. The plot shows significantly increased methylation levels of the ZBTB20 DMR region in individuals with MDD. (C) Case versus
control RPM counts for the DMR of ZBTB20 in 50 MZ twin pairs discordant for MDD.
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[27]. ZBTB20 is also crucial for the regionalization and
volume of the archicortex [28], which plays a role in de-
pression. In mice, mis-expression of ZBTB20 causes the
development of a compact homogenous pyramidal cell
layer within the hippocampal region, which is linked to
behavioural abnormalities [29].
Magnetic resonance imaging scans of MZT pairs dis-
cordant for MDD identified volume reduction in the left
posterior hippocampal region in the depressed co-twin
[30]. In MDD, the dentate gyrus, and pyramidal neuron
soma size is significantly decreased [31-34], suggesting
that altered neuronal development rather than outright
neuronal loss is responsible for the structural abnormal-
ities linked to depression [35]. This is consistent with
the pattern of reduced hippocampal volume and im-
paired regionalization suggested by the mouse model.
The DMR of ZBTB20 we identified is hypermethylated
in subjects with MDD and occurs within an identified
splice region, which may have the effect of creating dis-
tinct isoforms based upon the specific methylation profile.
ZBTB20 is also functionally related to the only SNP so far
associated with MDD to a genome-wide significance in a
genome-wide association study (common SNP rs1545843
(minor allele frequency = 0.41)) [36] occurring within the
gene SLC6A15, which like ZTBT20 is associated with hip-
pocampal structure. Down-regulation of SLC6A15 causes
a reduced hippocampal volume (an effect that was repli-
cated in stress-susceptible mice) and lower SLC6A15 ex-
pression in hippocampus reduces neural integrity and
excitatory neurotransmission in the brain.
ZBTB20 shows specific gene expression in the
hippocampus
Gene expression data of 932 brain samples from 10 differ-
ent brain regions from 101 unrelated individuals taken
from the Edinburgh Brain Bank (see Materials and
methods) showed that, in the overall dataset, ZBTB20
is highly expressed in the hippocampal, cerebellum and
white matter regions of the brain and lowly expressed
in the frontal, occipital and temporal cortex (Figure S1
in Additional file 1). A weighted gene co-expression net-
work analysis using WGCNA [37] generated a hippocam-
pus ZBTB20-cointaining module (with a total N = 216
genes) that was unique to the tissue (Z summary preserva-
tion statistic <10), suggesting that ZBTB20 is co-expressed
with a unique set of genes in the hippocampus, suggesting
it has a key function in its regulation (Figure 4).
RNA-seq data for MDD from NIMH Center for
Collaborative Genomic Studies on Mental Disorders
Data were adjusted for the confounding covariates BMI,
smoking, age, gender and various medication intake indica-
tors. No association between total gene expression level ofZBTB20 and MDD was observed (P-value >0.5). However,
two non-standard exons identified within ZBTB20 tran-
script variants (exon 33 in ENST00000463890 and exon 45
in ENST00000470556) are associated with unadjusted
P-values of 0.041 and 0.04, respectively. For these two
exons, we visually inspected the per-base read distribu-
tion in cases and controls, and observed a smooth shift
of mean expression levels across all bases in each case
(Figure S2 in Additional file 1). Both exons 33 and 45
are downstream of the DMR and are located at
114099729-114099787 and 114137901-114138014, re-
spectively. In the mouse homologue gene, Zbtb20, two
isoforms of the gene were shown to have distinct roles
in the development of the hippocampus [29]. The ex-
pression of non-standard exons in ZBTB20 may simi-
larly have an impact on the development and
regionalization of the human hippocampus.
Limitations
Several possible limitations to our study should be
noted. We used whole blood rather than brain samples
of discordant MZT pairs to identify methylation differ-
ences associated with MDD, which is sub-optimal but
clearly more accessible from living patients. Further-
more, if epigenetic studies are to be of clinical use, they
will ultimately have to rely upon peripheral tissue bio-
markers such as buccal, gut and white blood cells. How-
ever, a previous study comparing the methylation status
of pre-mortem blood and post-mortem brain tissue [2]
showed that significant variation in the methylation pro-
file of brain tissue can be reflected in blood. Also, recent
studies have shown that DMRs associated with both
chronic pain [38] and ageing are similar in brain and
blood tissue [39]. Although in the UK sample analyses of
anti-depressant treatment could not explain the ob-
served associations, other potential factors can not be
entirely eliminated. For example, birth weight and chor-
ionicity of the twin pair are possibly correlated with
adult methylation levels [40,41], but that information
was not available for the MZT pairs included in the
study. Another potential confounding factor in the
study was that the samples were predominately female.
Our RNA-seq validation data set was more evenly dis-
tributed than the initial study with 30% of the subjects
male (103 in case, 171 in control). It should, however, be
noted that the RNA-seq association is only of nominal sig-
nificance and would not retain significance if adjusted for
multiple testing.
Conclusions
Previous studies looking for genetic and epigenetic associa-
tions with MDD have largely been unsuccessful, possibly
due to the complexity of the phenotype or the heterogen-
eity of the population. A meta-analysis of 50 pairs of MZ
Figure 4 Weighted gene co-expression networks using WGCNA showing unique co-expression of ZBTB20 in the hippocampus from a
module containing 216 genes.
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of the genome consistently hypermethylated in the de-
pressed cohort, a result that was replicated in an unre-
lated case-control population. Excitingly, the DMR
occurs within the coding region of the ZBTBT20 gene,
which is associated with the structural integrity of the
hippocampus. This supports current research regard-
ing the etiology of MDD, which suggests it may be
driven by a disorder of neuron structure [42-44].
Analysis of brain tissue and expression data in the re-
gion also supports a model whereby misexpression of
ZBTB20 may be associated with depression. This study
represents the largest and most comprehensive study
so far of genome-wide methylation differences in MZ
pairs discordant for MDD and suggests that larger col-
laborative epigenetic twins studies are cost-effective
and could provide even more clues to the etiology of
complex traits.Materials and methods
The overall design was a meta-analysis of whole blood
genome-wide methylation in two cohorts of MZT
pairs discordant for MDD, followed by replication in
an independent case-control group and exploration
of expression and methylation signals in independent
brain tissue samples.Included subjects
The 27 MZT pairs (n = 54) of the UK samples were se-
lected from the TwinsUK Registry. The 54 participants
were all females aged 23 to 73 years, of European ances-
try and had no other psychiatric condition nor had they
been diagnosed with any known neurodegenerative dis-
order. The study was approved by the St Thomas’ Hos-
pital Research Ethics Committee (REC reference: EC04/
015). All participants in the study provided written
informed consent in accordance with the St Thomas’
Hospital Local Ethics Committee. UK twin pairs com-
pleted the Composite International Diagnostic Interview
questionnaire [45]. A diagnosis of MDD was constructed
from these questionnaires according to the DSM-IV cri-
teria [46]. Whole blood samples were collected from the
twins and stored at -80°C in EDTA tubes. DNA was ex-
tracted from 2 × 6 ml EDTA blood using the Nucleon
Genomic DNA Extraction Kit BACC3 and stored at -20°C
in TE Buffer.
The 23 MZT pairs of the Australian samples (n = 46)
were drawn from the Australian Twin Registry. The 46
participants comprised 7 male and 16 female MZ twin
pairs aged 25 to 73 years. Seven pairs were discordant
for smoking and a partially overlapping set of seven twin
pairs was discordant for alcohol dependence. The study
was approved by the Human Research Ethics Committee
of the Queensland Institute of Medical Research. The
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telephone interview, adapted from the Semi-Structured As-
sessment for the Genetics of Alcoholism (SSAGA) [47].
The SSAGA is a comprehensive psychiatric interview that
was designed to assess life-time psychiatric disorders in
adults according to DSM-III-R but subsequently updated
to DSM-IV criteria and modified for use as a telephone
survey instrument in Australia (SSAGA-OZ). SSAGA
also assesses history of alcohol dependence and tobacco
smoking with questions derived from the Composite
International Diagnostic Interview [48]. Structured in-
terviews were administered by trained telephone inter-
viewers, closely supervised by a clinical psychologist.
DNA was extracted from whole blood using a salt ex-
traction method [49].
Sample preparation for MeDIP-seq
All sample preparation and MeDIP-sequencing was per-
formed by the BGI-Shenzhen, Shenzhen, China. Extracted
DNA was fragmented using a Covaris sonication system
and sequencing libraries were prepared from 5 μg frag-
mented genomic DNA. End repair, <A > base addition and
adaptor ligation steps were performed using Illumina’s
Single-End DNA Sample Prep kit. Adaptor-ligated DNA
was immunoprecipitated by anti-5mC using a commercial
antibody (Diagenode), and MeDIP products were vali-
dated by quantitative PCR. MeDIP DNA was purified
with ZYMO DNA Clean & Concentrator-5 columns, and
amplified using adaptor-mediated PCR. DNA fragments
between 220 and 320 bp in size were gel-excised, and
amplification quality and quantity were evaluated by
Agilent BioAnalyzer analysis. The libraries were subjected
to highly parallel 50 bp single-end sequencing on the Illu-
mina HiSeq platform.
Sequencing quality control and alignment
From the raw fastq files, Illumina quality scores were
converted into Sanger Phred quality scores using MAQ
[50]. Quality control was performed on the raw se-
quence data using in-house scripts and FastQC [51].
After stringent quality control, an average of 19 million
uniquely mapped 50 bp reads were obtained from each
of the 100 samples. Alignment to hg19 was performed
using the Burrows-Wheeler algorithm [52]. The MED-
IPS package [53] was used to calculate RPM scores by
defining bin sizes of 500 bp with an overlap of 250 bp
across the genome (Figure 1). The total number of
500 bp bins generated by the MEDIPS packages was
12,145,229. The number of bins was filtered to include
only bins where more than 10% of samples had a read
coverage greater than 0. For the UK samples, this re-
duced the number to 11,132,286 bins, for the Australian
samples to 10,480,864. For both data sets, the raw FastQ
files and calculated RPM scores from the aligned dataare available from the Gene Expression Omnibus (GEO)
database [54]. The UK samples are Study ID GSE54222
and the Australian samples are Study ID GSM1313979.
Linear mixed effect models
A linear mixed effect model was fitted for the RPM values
of each 500 bp bin using the R package lmer [55]. Models
were derived separately for the UK and Australian co-
horts, reflecting the different fixed and random effects that
needed to be incorporated for the two datasets. For the
UK dataset, the linear mixed effect model incorporated
depression status, age, BMI, smoking and alcohol con-
sumption as fixed effects predictors [40,56-58] and twin
pair as random effect (Table S1 in Additional file 1). In
order to determine whether the discordant methylation
could be a result of anti-depressant medication, two
further linear mixed models were calculated. The first in-
cluded those individuals taking anti-depressant medica-
tion as an additional factor, the second eliminated twin
pairs where the depressed twin was taking medication
from the study (Tables S2 and S3 in Additional file 1). Re-
search has suggested that heterogeneity in whole blood
cell counts could confound estimates of DNA methylation
levels [59,60]. Cell count data were available for 21 twin
pairs in the UK dataset; the top hits from the linear mixed
model were analysed for evidence of association with cell
counts of lymphocytes, neutrophils, eosinophils, monocyte,
and total white blood and blood cell counts. For both data
sets, the variance in methylation for cases and controls was
compared for each bin.
The linear mixed effect model for the Australian data-
set also incorporated depression status, age, tobacco ad-
diction (yes/no) and alcohol dependence (yes/no) as
fixed effects and twin pair as a random effect; medica-
tion data were not available for these samples. Sex was
also incorporated as a fixed effect, but BMI was ex-
cluded, as this information was unavailable for four twin
pairs. We investigated the effect of BMI as a covariate by
fitting a second linear mixed effect model for the subset
of 19 Australian twin pairs with available BMI informa-
tion. Incorporating BMI as a fixed effect had only a
minor effect on the P-values observed for the DMRs
shown in Table S4 in Additional file 1.
Meta-analysis
As the UK and Australian datasets were drawn from dif-
ferent populations and modeled with different fixed ef-
fects, the data were integrated through a meta-analysis. A
fixed effect inverse variance meta-analysis was carried out
on all approximately 11 M bins of the UK and Australian
datasets, using GWAMA [61]. P-values were Bonferoni
adjusted to correct for multiple testing. We only present
results for DMRs that show no strong evidence for hetero-
geneity in the meta-analysis as evaluated by the Cochran’s
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(I2 < 0.75) [63].
Replication in independent case-control cohort of 354
unrelated females
Differentially methylated genes identified in the meta-
analysis of UK and Australian MZT pairs were evaluated
with the existing scientific literature to select for likely
MDD-related DMRs. Four DMRs were located within
genes related to the pathology of MDD and selected for
replication (see Results). For an independent case-control
replication we included blood MeDIP-seq data of 354 un-
related, age-matched females from the EpiTwin project,
118 suffering from MDD and 236 controls. MeDIP-seq
data of 118 cases and 236 controls were compared by
t-test (RPM values of each 500 bp bin).
Postmortem brain expression data obtained from the UK
Brain Expression Consortium
The four DMRs selected for replication were also com-
pared with an independent expression dataset of 932 post-
mortem brain samples collected from the Edinburgh Brain
Bank as part of the UK Brain Expression Consortium [64].
Expression data were generated with the Affymetrix Gene-
Chip Human Exon 1.0 ST Array and the dataset contains
932 brain samples of 10 different brain regions obtained
from 101 unrelated individuals (24 male and 77 female)
aged from 16 to 83 years. The 10 brain regions are cere-
bellum, frontal cortex, hippocampus, medulla, occipital
cortex, putamen, substantia niagra, temporal cortex, thal-
amus and intralobular white matter. The WGCNA R
package was used to analyze the data for incidence of con-
served co-expression gene networks [65].
Case-control MDD RNA-seq data
The cohort is of European ancestry and contains 463 indi-
viduals with recurrent MDD and 459 controls. A detailed
description of RNA-sequence and phenotype data for this
cohort is provided elsewhere [66,67]. RNA-sequencing
was performed using whole-blood, with an average yield
of 70 million reads per individual (50 or 51 bp, single-
ended). Reads were mapped to the NCBI v37 H. sapiens
reference genome using TopHat [68].Gene expression
data were directly obtained from the previous study on
this cohort [66]. Gene-level expression was quantified
using HTSeq [69]. Additionally, we used samtools mpi-
leup to quantify reads at each exonic position within the
gene [70]. Only uniquely aligned reads with base quality of
at least 30 were used for quantification. We then aggre-
gated reads within the start and end points of each distinct
exon identified in ENSEMBL Homo sapiens gene annota-
tion, and normalized by the total read depth of each li-
brary. Total gene expression and exon expression of
ZBTB20 were tested for association with MDD status.Associating testing followed the procedure reported previ-
ously for this cohort: a logistic regression likelihood ratio
test was used to test for association between expression
levels and MDD status while accounting for environmen-
tal, demographic, and medication intake covariates [66].
The list of covariates include age, gender, BMI, smoking
status, cholesterol and blood pressure medication intake
indicators. Genotype, raw RNA-seq, quantified expression,
and covariate data are available by application through
the NIMH Center for Collaborative Genomic Studies on
Mental Disorders. Instructions for requesting access to
data can be found at NIMH Repository and Genomics
Resource [71] and inquiries should reference the 'Depres-
sion Genes and Networks study' (D Levinson, PI) [66].
Additional file
Additional file 1: Table S1. linear mixed model on TwinsUK dataset
RPM values showing values for age, depression, smoking, alcohol and
BMI. The nearest gene feature to a DMR is shown; DMRs occurring within
a coding region are shown in bold. Table S2. linear mixed model on
RPM factoring values for age, depression, smoking, alcohol, BMI and
anti-depressant medication. The nearest gene feature to a DMR is shown,
DMRs occurring within a coding region are shown in bold. Table S3.
linear mixed model on RPM factoring values for age, depression, smoking,
alcohol and BMI removing twin pairs taking anti-depressant medication.
The nearest gene feature to a DMR is shown; DMRs occurring within a
coding region are shown in bold. Table S4. linear mixed model on
Queensland dataset RPM values showing values for age, depression,
smoking, alcohol and BMI. The nearest gene feature to a DMR is shown;
DMRs occurring within a coding region are shown in bold. Figure S1.
averaged expression values of the ZBTB20 gene across 10 brain regions.
Figure S2. ZBTBT20 exon 33 and exon 45 case-control comparison for
the RNA-seq expression data.
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